Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cardiff Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 2 filings
- 2 insiders, $1.05M in total
- Open-market sells
- 0 filings
- Insiders trading
- 2
- Net value
- +$1.05M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cardiff Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pace Gary W | Director | 2,043,661 | Jul 16, 2026 | 3 |
| Mohindru Mani | Chief Executive Officer | 59,067 | Jul 16, 2026 | 4 |
| Armitage James O | Director | 13,000Indirect | Jun 15, 2026 | 1 |
| Markin Rodney S | Director | – | Jun 15, 2026 | 1 |
| Tannenbaum Renee P | Director | 20,000 | Jun 15, 2026 | 1 |
| White Lale | Director | 113,788Indirect | Jun 15, 2026 | 1 |
| Aggarwal Ajay | Chief Operating Officer | – | Apr 28, 2026 | 1 |
| Muntner Joshua B | Chief Financial Officer | – | Apr 16, 2026 | 1 |
| Smeal Tod | Chief Scientific Officer | – | Apr 16, 2026 | 1 |
| Lindsay Brigitte Ute | Chief Accounting Officer | – | Feb 18, 2026 | 1 |
| Levine James E. | Chief Financial Officer | 67,716Indirect | Mar 13, 2025 | 0 |
| Erlander Mark | Chief Executive Officer | 24,481 | Mar 13, 2025 | 0 |
| Kabbinavar Fairooz | Chief Medical Officer | – | Mar 13, 2025 | 0 |
| Kelemen Vicki | Exec. VP and COO | – | Mar 16, 2023 | 0 |
| Brancaccio John P | Other: Former Director | – | Jun 9, 2022 | 0 |
| Ruffner Katherine L | Chief Medical Officer | – | Mar 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 (view filing)4:03 PM ET | Jul 14 | 2 days | Pace Gary WDirector | PPurchase | +687.3K | $1.46 | +$1.00M | +50.7%2.04M after | |
| Jul 16, 2026 (view filing)4:03 PM ET | Jul 14 | 2 days | Pace Gary WDirector | PPurchase | +687.3K | $0.00 | $0 | –687.3K after | Derivative |
| Jul 16, 2026 (view filing)4:01 PM ET | Jul 14 | 2 days | Mohindru ManiChief Executive Officer | PPurchase | +34.4K | $1.46 | +$50.0K | +139.1%59.1K after | |
| Jul 16, 2026 (view filing)4:01 PM ET | Jul 14 | 2 days | Mohindru ManiChief Executive Officer | PPurchase | +34.4K | $0.00 | $0 | –34.4K after | Derivative |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Mohindru ManiChief Executive Officer | PPurchase | +24.7K | $1.21 | +$29.9K | New position24.7K after | |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Pace Gary WDirector | PPurchase | +30.0K | $1.22 | +$36.6K | +2.3%1.36M after | |
| Jul 31, 2025 (view filing) | Jul 30 | 1 day | Pace Gary WDirector | PPurchase | +275.0K | $2.45 | +$673.8K | +26.0%1.33M after | |
| Jul 31, 2025 (view filing) | Jul 30 | 1 day | Pace Gary WDirector | PPurchase | +15.0K | $2.45 | +$36.8K | +1.1%1.35M after | |
| Dec 18, 2024 (view filing) | Dec 16-18 | 2 days | Levine James E.Chief Financial Officer | PPurchase | +7.72K | $4.76 | +$36.7K | +12.9%67.7K after | 3 lots |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Tannenbaum Renee PDirector | PPurchase | +10.0K | $3.42 | +$34.2K | +100.0%20.0K after | |
| Dec 12, 2024 (view filing) | Dec 11 | 1 day | Pace Gary WDirector | PPurchase | +350.1K | $2.60 | +$910.3K | +50.2%1.05M after | |
| Dec 12, 2024 (view filing) | Dec 11 | 1 day | Pace Gary WDirector | PPurchase | +11.5K | $2.60 | +$29.9K | +1.1%1.06M after | |
| Dec 19, 2023 (view filing) | Dec 19 | Same day | Pace Gary WDirector | PPurchase | +30.0K | $1.37 | +$41.1K | +4.5%697.8K after | |
| Nov 14, 2023 (view filing) | Nov 10 | 4 days | Pace Gary WDirector | PPurchase | +22.9K | $0.98 | +$22.5K | +3.6%667.8K after | |
| Nov 29, 2022 (view filing) | Nov 25 | 4 days | Erlander MarkChief Executive Officer | PPurchase | +10.0K | $1.43 | +$14.3K | +69.1%24.5K after | |
| Oct 11, 2022 (view filing) | Sep 16 | 25 daysLate | Armitage James ODirector | PPurchase | +13.0K | $1.56 | +$20.3K | New position13.0K after | |
| Sep 20, 2022 (view filing) | Sep 19 | 1 day | White LaleDirector | PPurchase | +15.0K | $1.64 | +$24.6K | +15.2%113.8K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Tannenbaum Renee PDirector | PPurchase | +10.0K | $1.72 | +$17.2K | New position10.0K after | 2 lots |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Pace Gary WDirector | PPurchase | +150.0K | $1.71 | +$256.5K | +30.3%644.8K after | |
| Sep 19, 2022 (view filing) | Sep 16 | 3 days | Levine James E.Chief Financial Officer | PPurchase | +30.0K | $1.56 | +$46.8K | +100.0%60.0K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Pace Gary WDirector | PPurchase | +30.0K | $6.75 | +$202.5K | +6.5%494.8K after | |
| Sep 13, 2021 (view filing) | Sep 10 | 3 days | Levine James E.Chief Financial Officer | PPurchase | +30.0K | $6.47 | +$194.0K | New position30.0K after | 5 lots |